LUMOS PHARMA, INC.
LUMOS PHARMA, INC. (NLNK): 8 pipeline candidates · ~9 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.8 months
D/E 2.55 · 0% dilution
Lead: Approved
8 candidates
N/A
N/A
A transparent, data-derived signal for LUMOS PHARMA, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$13.5M
Quarterly Burn
$5.0M
Runway
8.8 mo
Revenue
$726K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| febridx bacterial / non-bacterial point of care assay | — |
| febridx bacterial/non-bacterial assay | — |
| lidocaine | Approved |
| lum-201 | Phase 3 |
| lumos | — |
| null | — |
| prismira | — |
| rhgh norditropin pen | Phase 2 |
Frequently asked questions
How many drug candidates are in LUMOS PHARMA, INC.'s pipeline?
LUMOS PHARMA, INC. (NLNK) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is LUMOS PHARMA, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, LUMOS PHARMA, INC. has approximately 8.8 months of cash runway.
Who is the CEO of LUMOS PHARMA, INC.?
Stockholders Richard is the chief executive officer of LUMOS PHARMA, INC. (NLNK).
Get the full picture on LUMOS PHARMA, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.